MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Revance Therapeutics Company Profile (NASDAQ:RVNC)

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $43.80 (221.59% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Brean CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016SunTrust Banks Inc.Lower Price TargetBuy$46.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$54.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016GuggenheimReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015William BlairReiterated RatingBuy$59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.83)($0.71)$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q415($0.84)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.69)($0.65)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015($0.53)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.69)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.68)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q1 14($0.87)($1.93)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.07)($0.66)($0.87)
Q2 20162($0.91)($0.91)($0.91)
Q3 20162($0.95)($0.93)($0.94)
Q4 20162($1.02)($0.95)($0.99)
(Data provided by Zacks Investment Research)
Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
DateHeadline
06/29/16 08:58 AMEquity Research and Technical Review on Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph
06/29/16 08:58 AMRevance Therapeutics Inc (RVNC) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 06:53 PMRevance Therapeutics, Inc. (NasdaqGM:RVNC) Stock Momentum Hits Weakness - CML News
06/23/16 06:53 PMBrokers Issue Average Price Target Of 42.33 On Revance Therapeutics Inc (RVNC) - Fiscal Standard
06/21/16 10:32 AMInvestigation for Investors in Shares of Revance Therapeutics Inc (NASDAQ:RVNC) Announced
06/20/16 05:55 PMRevance Therapeutics Inc (RVNC) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 05:58 PMRevance Therapeutics Inc. (RVNC) is Trading Higher on Unusual Volume for June 15 - Equities.com
06/15/16 06:08 PMPerformance report of the company: Revance Therapeutics, Inc. (NASDAQ:RVNC) - News Oracle
06/15/16 06:08 PMRevance Therapeutics Inc. (RVNC) Sank To A New Low On Study Results - RTT News
06/15/16 06:08 PMRevance Therapeutics Inc. (RVNC) Jumps 7.19% on June 15 - Equities.com
06/15/16 10:45 AMTrending Stocks Update: Navistar International Corporation (NYSE:NAV), Revance Therapeutics, Inc. (NASDAQ:RVNC) - Beacon Chronicle
06/15/16 10:45 AMAnalyst Downgrades: Baidu Inc (ADR), Revance Therapeutics Inc, and Chesapeake Energy Corporation - Schaeffers Research (blog)
06/15/16 10:45 AMSummary of Analyst's Study: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Revance Therapeutics, Inc ... - Street Updates
06/14/16 05:57 PMRevance Therapeutics Drops on Missed Late Stage Results
06/14/16 05:57 PMRevance Therapeutics Inc (NASDAQ:RVNC) Might Be Oversold On Its Latest Discontinuation
06/14/16 10:59 AMMoonlight Vista Sees Potential In Wowo (JMU); Revance Therapeutics (RVNC) Slips Into Negative Zone
06/14/16 10:59 AMRevance Therapeutics Inc. (RVNC) Is Down After Phase 3 Study Failed
06/14/16 10:59 AMRevance Therapeutics (RVNC) Announces RT001 REALISE 1 Phase 3 Missed co-Primary, Other Endpoints
06/14/16 10:59 AMRevance's Lead Candidate Fails in Phase III Crow's Feet Study
06/14/16 10:59 AMAnalyst Downgrades: Baidu Inc (ADR), Revance Therapeutics Inc, and Chesapeake Energy Corporation
06/14/16 10:59 AMRevance Therapeutics Inc. (RVNC) Is Sinking On Disappointing Study Results
06/14/16 10:48 AMWhy is Revance Therapeutics (RVNC) Stock Plummeting Today? -
06/14/16 10:45 AMWhy Revance Therapeutics Is Crashing 23% Today -
06/14/16 10:20 AMRevance Therapeutics (RVNC) Stock Plunging on Drug Results -
06/14/16 09:05 AMBrean Downgrades Revance Therapeutics Following RT-001 Fail - Brean Capital's Difei Yang downgraded Revance Therapeutics Inc (NASDAQ: RVNC) from Buy to Hold and removed the price target. The downgrade came after RT-001 failed a Phase III study for Crow's Feet. Related Link: Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out Besides RT-001's failure, Yang needed "more clarity on the Phase ...Full story available on Benzinga.com
06/13/16 05:47 PMRevance Therapeutics Inc. (RVNC) Is Down After Phase 3 Study Failed - RTT News
06/13/16 05:27 PMUPDATE 1-Revance to stop developing crow's feet drug after trial failure - June 13 (Reuters) - Revance Therapeutics Inc said it would discontinue the development of its drug to treat crow's feet after the topical gel failed a late-stage study.
06/13/16 03:48 PMRevance shares drop after crow's-feet treatment study fails -
06/13/16 03:25 PMRevance to stop developing crow's feet drug after trial failure - [Reuters] - Revance Therapeutics Inc said it would discontinue the development of its drug to treat crow's feet after the topical gel failed a late-stage study. The drug, codenamed RT001, was being studied for the ...
06/13/16 07:39 AMRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : June 13, 2016 -
06/08/16 09:15 AMREVANCE THERAPEUTICS INC. (NASDAQ:RVNC) Financial Condition Compared to S&P 500 - CML News
06/03/16 04:08 PMREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/03/16 02:39 PMETF’s with exposure to Revance Therapeutics, Inc. : June 3, 2016 -
06/03/16 09:10 AMRevance Therapeutics Inc. (RVNC) is Trading Lower on Unusual Volume for June 01 - Equities.com
06/02/16 05:13 PMRevance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio - [GlobeNewswire] - -Portfolio covers diverse and novel indications, compositions and formulations-. -Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders-. NEWARK, Calif., June 02, ...
06/01/16 06:49 PMRevance Therapeutics Inc. (RVNC) Drops 6.39% on June 01 - Equities.com - Revance Therapeutics Inc. (RVNC) Drops 6.39% on June 01Equities.comRevance Therapeutics Inc. (RVNC) was one of the Russell 2000's biggest losers for Wednesday June 01 as the stock slid 6.39% to $19.19, a loss of $-1.31 per share. Starting at an opening price of $20.49 a share, the stock traded between $19.03 and $20 ...Analyst Review: Revance Therapeutics Inc (RVNC)Risers & FallersAre Analysts Bullish Revance Therapeutics Inc (NASDAQ:RVNC) After Last Week?The PostRevance to Participate in Upcoming Investor ConferencesGlobeNewswire (press release)all 8 news articles »
05/31/16 06:31 PMStock Review and Earnings Check on Revance Therapeutics, Inc. (NASDAQ:RVNC) - HNN - Stock Review and Earnings Check on Revance Therapeutics, Inc. (NASDAQ:RVNC)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Revance Therapeutics, Inc.and more »
05/31/16 03:05 PMRevance to Participate in Upcoming Investor Conferences - [GlobeNewswire] - NEWARK, Calif., May 31, 2016-- Revance Therapeutics, Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company ...
05/30/16 01:59 PMTarget Check and Stock Performance Recap Revance Therapeutics, Inc. (NASDAQ:RVNC) - HNN - Target Check and Stock Performance Recap Revance Therapeutics, Inc. (NASDAQ:RVNC)HNNIn recent session activity, Revance Therapeutics, Inc. (NASDAQ:RVNC) shares have traded +1.28%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been ...and more »
05/27/16 01:08 PMTargeted Movers: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) , Revance Therapeutics, Inc. (NASDAQ:RVNC) - Street Updates - Targeted Movers: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) , Revance Therapeutics, Inc. (NASDAQ:RVNC)Street UpdatesOn 5/25/2016, shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rose +2.9645% in trading session and finally closed at $0.4932. The company most recent volume stood at 166.71 thousand shares as compared to its average volume of 202 thousand ...
05/26/16 12:11 PMStock Rating Review for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Wall Street Hints and News - Stock Rating Review for Revance Therapeutics, Inc. (NASDAQ:RVNC)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Revance Therapeutics, Inc. (NASDAQ:RVNC). Covering ...and more »
05/26/16 12:11 PMRevance Therapeutics Inc (RVNC) Jumps 9.84% on May 24 - Equities.com - Revance Therapeutics Inc (RVNC) Jumps 9.84% on May 24Equities.comRevance Therapeutics Inc (RVNC) was among the biggest gainers on the Russell 2000 for Tuesday May 24 as the stock popped 9.84% to $19.53, representing a gain of $1.75 per share. Some 393,274 shares traded hands on 3,304 trades, compared with an ...Revance Therapeutics Incorporated (NASDAQ:RVNC) Shorted Shares Decreased By 3.58%Franklin IndependentRevance Therapeutics, Inc. (NASDAQ:RVNC) Costs Of Goods Sold Stands At $0.005 MillionsStocks Dailyall 3 news articles »
05/24/16 01:05 PMTarget Check and Stock Performance Recap Revance Therapeutics, Inc. (NASDAQ:RVNC) - Wall Street Hints and News - Target Check and Stock Performance Recap Revance Therapeutics, Inc. (NASDAQ:RVNC)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Revance Therapeutics, Inc.
05/23/16 07:26 AMRevance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : May 23, 2016 -
05/21/16 12:27 PMRevance Therapeutics Inc (RVNC) Jumps 7.19% on May 20 - Equities.com - Revance Therapeutics Inc (RVNC) Jumps 7.19% on May 20Equities.comRevance Therapeutics Inc (RVNC) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 7.19% to $18.34, representing a gain of $1.23 per share. Some 154,404 shares traded hands on 1,457 trades, compared with an ...and more »
05/20/16 12:52 PMRevenue Update on Revance Therapeutics Inc(NASDAQ:RVNC) - Trade Calls - Revenue Update on Revance Therapeutics Inc(NASDAQ:RVNC)Trade CallsRevance Therapeutics Inc(NASDAQ:RVNC) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 9, 2016. Company reported revenue of $75.00K. Analysts estimated a revenue of $70.00K. Earnings per ...and more »
05/20/16 11:04 AMETF’s with exposure to Revance Therapeutics, Inc. : May 20, 2016 -
05/19/16 01:34 PMRevance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/19/16 12:28 PMRevance Therapeutics, Inc. (RVNC) - Medical Equipment - Deals and Alliances Profile - New Market Study Published - (live-PR.com) - Revance Therapeutics, Inc. (Revance) is a bio-pharmaceutical company that develops, manufactures and commercializes novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company's products include RT001, a ...
05/18/16 01:11 PMNoteworthy Tuesday Option Activity: RVNC, OFG, WWE - Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Revance Therapeutics Inc (Symbol: RVNC), where a total volume of 852 contracts has been traded thus far today, a contract volume which is ...
About Revance Therapeutics

Revance Therapeutics logoRevance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RVNC
  • CUSIP:
Key Metrics:
  • Previous Close: $13.62
  • 50 Day Moving Average: $16.84
  • 200 Day Moving Average: $20.57
  • P/E Ratio: N/A
  • P/E Growth: -0.31
  • Market Cap: $387.71M
  • Current Quarter EPS Consensus Estimate: $-3.53 EPS
Additional Links:
Revance Therapeutics (NASDAQ:RVNC) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha